PCaI patient education conference: March 2, Ft. Myers, FL

Prostate Cancer International (PCaI) is excited to be holding its next patient education / information conference in Fort Myers, FL, on March 2, 2019, from 9:00 a.m. to 5:00 p.m. For complete details of the meeting agenda, the speakers, how to register, and other facts, please click here. … READ MORE …

Prostate ablation using HIFU — the role of patient preference information

A newly published review by staff of the Center for Devices and Radiological Health (CDRH at the U.S. Food & Drug Administration (FD) addresses the potential role for patient preference information (PPI) in determining patient perceptions of the “value” of high-intensity focused ultrasound (HIFU) and similar techniques in the management of prostate cancer. … READ MORE …

“If you can’t explain it simply, you don’t understand it well enough”

Many readers of this blog site might find this video (or the transcript) to be informative … or just entertaining. It’s primarily intended for physicians and their support staff.

Help with finding out about clinical trials for prostate cancer treatment

Apparently the National Cancer Institute (NCI) has just re-funded the Fred Hutchinson Cancer Research Center in Seattle to the tune of $24 million to continue to operate what we see as an important, patient-centric program here in the USA that we (and therefore probably many others) were utterly unaware of. … READ MORE …

Finding common ground on how “best” to treat localized prostate cancer, and what to tell the patients

One of the hardest issues for newly diagnosed prostate cancer patients to deal with has long been the differences in opinion between physicians about appropriate first-line treatment (and the relevant information they are offered) — most especially for patients with localized disease. … READ MORE …

Clinical trial design, clinical advice to patients, and clinical decision-making: not the same thing at all

In a recent opinion piece in the Journal of Clinical Oncology, Dr. Anthony D’Amico (a prostate cancer specialist for whom we have great respect) has again aired his concerns about risk for progression to metastatic disease among men on active surveillance. … READ MORE …

“Competitive analysis” in the development of drugs for advanced prostate cancer

So the other morning your sitemaster learned that a relatively new FirstWord Therapy Report had come out that dealt with future use of biopharmaceuticals in the treatment of progressive and advanced prostate cancer. … READ MORE …